Thus, reduced TET2 function, due to loss-of-function mutations, reduced mRNA expression due to epigenetic silencing or not yet elucidated mechanisms may have a great contribution to the malignant phenotype of hematological cancers. The gene discussed is TET2; the disease is hematopoietic and lymphoid cell neoplasm.